Erin M. Bertino, MD, a medical oncologist at The Ohio State University Comprehensive Cancer Center—James, discusses the impact of the 

-mutated subset analysis of the phase 3 IMpower150 trial on the use of immunotherapy in patients with non—small cell lung cancer (NSCLC).

The IMpower150 trial randomized patients with stage IV nonsquamous NSCLC 1:1:1 to receive either atezolizumab (Tecentriq) plus bevacizumab (Avastin) and carboplatin/paclitaxel (ABCP); atezolizumab plus carboplatin/paclitaxel (ACP); or bevacizumab plus carboplatin/paclitaxel (BCP).

Results showed improved progression-free survival and overall survival (OS) with the quadruplet regimen in all-comers with metastatic nonsquamous NSCLC who had not previously received chemotherapy. Additionally, patients with 

-mutant NSCLC also derived benefit from ABCP, though OS was not statistically significant.

Data from the IMpower150 and IMpower130 trials showed limited efficacy with the combination of chemotherapy and immunotherapy in this subgroup of patients.

While ABCP is not an FDA-approved treatment for patients with 

-mutant NSCLC, it could be applicable in the second-line setting for patients who progress on frontline osimertinib (Tagrisso) where limited options are available, concludes Bertino.

Videos

Erin M. Bertino, MD, discusses the impact of the EGFR-mutated subset analysis of the phase 3 IMpower150 trial on the use of immunotherapy in patients with non–small cell lung cancer.

Dr. Bertino on the Impact of the EGFR-Mutated Subset Analysis of IMpower150 in NSCLC

Erin M. Bertino, MD, a medical oncologist at The Ohio State University Comprehensive Cancer Center—James, discusses the use of dacomitinib (Vizimpro) in the treatment of patients with non–small cell lung cancer (NSCLC) with 

 mutations and its place among other available EGFR TKIs.

 for use in the frontline treatment of patients with metastatic NSCLC with 

 exon 19 deletion or exon 21 L858R substitution mutations. The regulatory decision was based on data from the phase III ARCHER 1050 trial, in which dacomitinib was compared head-to-head with gefitinib (Iressa). Results from the trial showed that dacomitinib led to improved progression-free survival over gefitinib, says Bertino. Now, 5 FDA-approved EGFR inhibitors are available in this space. However, it is unclear how dacomitinib will fit into the treatment landscape, adds Bertino.

In the United States, there will likely be continued use of osimertinib (Tagrisso) because of its favorable toxicity profile and positive data, according to Bertino. Finding a place for dacomitinib is going to be challenging, adds Bertino; this agent is likely to fall into the same category as erlotinib (Tarceva), gefitinib, and afatinib (Gilotrif), which all play second fiddle to osimertinib, Bertino concludes.

Erin M. Bertino, MD, discusses the use of dacomitinib (Vizimpro) in the treatment of patients with non–small cell lung cancer with EGFR mutations and its place among other available EGFR TKIs.

Dr. Bertino on Frontline Dacomitinib in Metastatic EGFR+ NSCLC

Erin M. Bertino, MD, a medical oncologist at The Ohio State University Comprehensive Cancer Center—James, discusses the potential impact of the novel coronavirus 2019 (COVID-19) on patients with lung cancer.

Patients with thoracic malignancies may be especially vulnerable to COVID-19 because they are also predisposed to pneumonitis and pneumonia. Additionally, these patients, some of whom are smokers, may have underlying chronic obstructive pulmonary disease and heart disease, says Bertino.

In order to reduce the risk of contracting the virus, Bertino recommends patients avoid those who are sick and large crowds until the virus can be contained. Additionally, patients who are already sick should avoid coming to the clinic to reduce the spread of the virus to other immunocompromised individuals, concludes Bertino.

Erin M. Bertino, MD, a medical oncologist at The Ohio State University Comprehensive Cancer Center–James, discusses the potential impact of the novel coronavirus 2019 (COVID-19) on patients with lung cancer.

Erin M. Bertino, MD

Articles

Dr. Bertino on the Impact of the EGFR-Mutated Subset Analysis of IMpower150 in NSCLC

Dr. Bertino on Frontline Dacomitinib in Metastatic EGFR+ NSCLC

Dr. Bertino on the Impact of COVID-19 on Patients With Lung Cancer